![](https://investorshub.advfn.com/uicon/58431.png?cb=1505481885)
Tuesday, April 02, 2019 1:04:04 PM
Tue April 2, 2019 7:00 AM|Business Wire|About: VSTM
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20190402005118r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005118/en/
Verastem Oncology:
Rob Gagnon
Chief Financial Officer
+1 781-469-1681
rgagnon@verastem.com
Investors:
Joseph Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com
Source: Verastem, Inc.
Copyright Business Wire 2019
Recent VSTM News
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:56 PM
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 05/09/2024 08:02:00 PM
- Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 11:30:00 AM
- Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer • Business Wire • 04/18/2024 08:05:00 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/04/2024 11:30:00 AM
- Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer • Business Wire • 03/18/2024 11:00:00 AM
- Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates • Business Wire • 03/14/2024 08:05:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/11/2024 09:07:54 PM
- Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs • Business Wire • 03/11/2024 11:30:00 AM
- Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 03/05/2024 10:27:00 PM
- Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 • Business Wire • 03/05/2024 09:30:00 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 02/08/2024 09:22:55 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:49:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 09:01:10 PM
- Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers • Business Wire • 01/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 12:54:28 PM
- Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 01/18/2024 09:00:00 PM
- Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference • Business Wire • 01/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 09:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:02:35 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM